Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | HSD11B1 | P28845 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14788450 | 0.79 | TSHR (0.59) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL3760260 | 0.79 | TSHR (0.59) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL25078296 | 0.79 | TSHR (0.46) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL30949274 | 0.79 | TSHR (0.46) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL31245629 | 0.77 | SMN1; SMN2 (0.49) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL28236734 | 0.76 | TSHR (0.56) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL23329191 | 0.76 | TSHR (0.56) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL23328981 | 0.76 | TSHR (0.56) | TSHRMEN1KMT2ACYP1A2CYP2C19 | |
| SCHEMBL9910775 | 0.75 | HSD11B1 (0.47) | TSHRALDH1A1HSD11B1SMN1; SMN2PTGS1 | |
| SCHEMBL24469923 | 0.75 | TSHR (0.58) | TSHRMEN1KMT2ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307204-A4 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2004-06-02 | — | — | EP | claimed |
| EP-1307204-A1 | PROTEASE INHIBITORS | SmithKline Beecham Corporation (US) | 2003-05-07 | — | — | EP | claimed |
| WO-2001095911-A1 | PROTEASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-12-20 | — | — | WO | claimed |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2023-08-03 | — | — | US | disclosed |
| WO-2022270980-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2022-12-29 | — | — | WO | disclosed |
| US-11377425-B1 | Small molecule modulators of IL-17 | LEO PHARMA A/S (DK) | 2022-07-05 | — | — | US | disclosed |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-11-03 | — | — | US | disclosed |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | BRISTOL MYERS SQUIBB CO (US) | 2020-04-23 | — | — | US | disclosed |
| EP-3632919-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | Bristol-Myers Squibb Company (US) | 2020-04-08 | — | — | EP | disclosed |
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-20180212158-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2018-07-26 | — | — | US | disclosed |
| US-20070299052-A1 | Inhibitors of IAP | GENENTECH, INC. (US) | 2007-12-27 | — | — | US | disclosed |
| US-20070219140-A1 | IAP BIR domain binding compounds | AEGERA THERAPEUTICS, INC. (CA) | 2007-09-20 | — | — | US | disclosed |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | MSD K.K. (JP) | 2007-07-26 | — | — | US | disclosed |
| US-7244851-B2 | 1-[2-Cyclohexyl-2-(2-methylamino-propionylamino)-acetyl]-pyrrolidine-2-carboxylic acid (2-phenyl-2H-pyrazol-3-yl)-amide; inhibitors of IAP, for treating malignancies | GENENTECH, INC. (US) | 2007-07-17 | — | — | US | disclosed |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | AEGERA THERAPEUTICS, INC. (CA) | 2007-04-26 | — | — | US | disclosed |
| US-20070088166-A1 | Clickphosphines for transition metal-catalyzed reactions | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2007-04-19 | — | — | US | disclosed |
| EP-1726585-A1 | DIARYL-SUBSTITUTED FIVE-MEMBERED HETEROCYCLE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-11-29 | — | — | EP | disclosed |
| US-6946462-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-6869953-B2 | N-monoacylated derivatives of o-phenylenediamines, their analogs and their use as pharmaceutical agents | HOFFMAN-LA ROCHE INC. (US) | 2005-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428077-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | TSHR 147/4885MEN1 3023/4885KMT2A 4125/4885 |
| US-20200123160-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, TMPRSS4, F2R | TSHR 147/4885MEN1 3023/4885KMT2A 4125/4885 |
| US-20070093428-A1 | Inhibitors of apoptosis proteins (IAP); antiproliferative agents; anticancer agents; death receptor agonist; | BAD, BIRC5, BAX | TSHR 678/4885MEN1 1860/4885KMT2A 4730/4885 |
| US-20070173507-A1 | Dairyl-substituted five-membered heterocycle derivative | OPRK1, OPRL1, GRM1 | TSHR 1713/4885MEN1 4649/4885KMT2A 4006/4885 |
| US-11377425-B1 | Small molecule modulators of IL-17 | IL17A, IL15, IL2 | TSHR 4390/4885MEN1 2191/4885KMT2A 3095/4885 |
| US-20070299052-A1 | Inhibitors of IAP | XIAP, BIRC5, BIRC3 | TSHR 2845/4885MEN1 1510/4885KMT2A 3374/4885 |
| US-20180212158-A1 | ORGANIC LIGHT-EMITTING DIODE MATERIALS | MSN, DDT, NECTIN4 | TSHR 3857/4885MEN1 122/4885KMT2A 1200/4885 |
| US-20070219140-A1 | IAP BIR domain binding compounds | BIRC5, BIRC2, BIRC8 | TSHR 3974/4885MEN1 863/4885KMT2A 4661/4885 |
| US-20230242535-A1 | IMIDAZOTHIADIAZOLE AND IMIDAZOPYRAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION | F2RL3, F2R, TMPRSS4 | TSHR 128/4885MEN1 3037/4885KMT2A 4056/4885 |
| US-20070088166-A1 | Clickphosphines for transition metal-catalyzed reactions | WEE1, WEE2, ITK | TSHR 1041/4885MEN1 329/4885KMT2A 611/4885 |
| US-10822343-B2 | Imidazothiadiazole and imidazopyrazine derivatives as protease activated receptor4 (PAR4) inhibitors for treating platelet aggregation | F2RL3, TMPRSS4, F2R | TSHR 147/4885MEN1 3023/4885KMT2A 4125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.